Skip to main content
. 2019 Mar 18;10:209. doi: 10.3389/fphar.2019.00209

Table 1.

Baseline clinical characteristics and their effects on pharmacokinetics and the recovery of platelet function in 51 healthy subjects.

Variable N (%) or Mean ± SD Comparison with 7 days post-dosea P-value of ticagrelor P-value of M8 RT50† RECDAY†
t1/2 Tmax Cmax AUC t1/2 Tmax Cmax AUC
Age (years) 24.51 ± 2.32 / 0.632 0.748 0.137 0.986 0.163 0.366 0.107 0.675 0.109 0.012
Male 27 (52.94%) / 0.004 0.010 0.122 0.865 0.497 0.034 0.007 <0.001 0.149 0.014
BMI, kg/m2 20.69 ± 2.32 / 0.986 0.805 0.079 0.696 0.358 0.757 0.125 0.062 0.130 0.108
LABORATORY CHARACTERISTICS
FIB, g/L 2.74 ± 0.46 0.880 0.206 0.072 0.219 0.165 0.345 0.198 0.060 0.003 0.702 0.469
APTT, sec 38.24 ± 3.69 0.108 0.346 0.838 0.900 0.859 0.577 0.798 0.735 0.208 0.750 0.284
TT, sec 16.34 ± 0.90 0.880 0.079 0.788 0.601 0.526 0.769 0.042 0.788 0.012 0.551 0.206
PT-A, % 98.29 ± 8.68 0.018 0.209 0.374 0.624 0.191 0.253 0.505 0.245 0.166 0.989 0.754
PT, sec 13.3 ± 0.46 <0.001 0.531 0.502 0.864 0.402 0.456 0.456 0.190 0.124 0.369 0.643
INR 1.01± 0.05 <0.001 0.459 0.209 0.734 0.349 0.978 0.560 0.814 0.204 0.206 0.983
WBC, 10∧9/L 6.05 ± 1.06 0.075 0.472 0.692 0.167 0.692 0.580 0.506 0.150 0.458 0.675 0.835
RBC1, 10∧9/L 4.86 ± 0.62 0.261 0.069 0.155 0.174 0.953 0.420 0.116 0.014 <0.001 0.345 0.353
MCH, pg 29.30 ± 2.16 0.698 0.817 0.768 0.609 0.493 0.626 0.394 0.747 0.449 0.397 0.921
PLT, 10∧9/L 229.49 ± 47.84 0.154 0.483 0.758 0.923 0.356 0.937 0.324 0.751 0.502 0.269 0.414
URIC, umol/L 342.81 ± 76.14 0.305 0.004 0.029 0.996 0.054 0.529 0.778 0.121 0.036 0.198 0.036
CREA, umol/L 71.13 ± 13.97 0.007 0.064 0.030 0.009 0.058 0.960 0.144 0.055 <0.001 0.988 0.326
ALT, U/L 17.33 ± 9.86 0.569 0.312 0.791 0.011 0.589 0.414 0.327 0.003 0.007 0.794 0.923
TP, g/L 73.46 ± 5.01 0.164 0.985 0.998 0.975 0.768 0.682 0.975 0.312 0.560 0.558 0.066
ALB, g/L 46.01 ± 2.96 0.205 0.756 0.457 0.127 0.427 0.567 0.835 0.071 0.407 0.754 0.004
DBIL, umol/L 4.48 ± 0.92 0.502 0.806 0.328 0.168 0.170 0.136 0.388 0.286 0.003 0.576 0.860
TBIL, umol/L 15.80 ± 5.51 0.004 0.578 0.386 0.201 0.500 0.691 0.975 0.073 0.018 0.574 0.590
Heart rate, bpm 67.51 ± 9.31 0.873 0.302 0.580 0.304 0.425 0.008 0.020 0.491 0.331 0.365 0.385
T interval, ms 408.43 ± 25.45 0.379 0.226 0.908 0.368 0.718 0.046 0.039 0.378 0.393 0.660 0.326
ADP, % 68.18 ± 6.35 / 0.439 0.724 0.941 0.829 0.710 0.950 0.938 0.350 0.154 0.038
ERYb 6 (11.76%) / 0.952 0.339 0.244 0.492 0.720 0.731 0.227 0.698 0.453 0.576
RBC2 – / / / / / / / / / / /
OB – / / / / / / / / / / /

BMI, body mass index; FIB, fibrinogen; APTT, activated partial thromboplastin time; TT, thrombin time; PT-A, prothrombin activity; PT, prothrombin time; INR, international normalized ratio; WBC, white blood cell count; RBC1, red blood cell count; MCH, mean corpuscular hemoglobin; PLT, platelet count; URIC, uric acid; CREA, creatinine; ALT, alanine aminotransferase; TP, total protein; ALB, albumin; DBIL, direct bilirubin; TBIL, total bilirubin; ADP, RBC2, red blood cell in urine; ERY, erythrocyte; OB, stool occult blood test; C max, Peak concentration; T max, time of peak concentration; t1/2, elimination half-life; AUC, area of plasma concentration–time curve; RT50, time to 50% recovery of maximum drug effect; RECDAY, recover day to the baseline PA. All correlation analyses were undertaken using Spearman correlation coefficients except those variables marked a, b.

a

Repeated measures data ANOVA.

b

Mann-Whitney U-test.

†

RT50 and RECDAY were successfully acquired in 47 subjects.

The color values refer to the results with P < 0.05 that considered as significant.